Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1a/1b dose-escalating trial of VE303 in healthy volunteers.

Trial Profile

Phase 1a/1b dose-escalating trial of VE303 in healthy volunteers.

Phase of Trial: Phase I

Latest Information Update: 12 Dec 2018

At a glance

  • Drugs VE 303 (Primary) ; Vancomycin
  • Indications Clostridium difficile infections
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 12 Dec 2018 Status changed from recruiting to completed, according to a PureTech Health media release.
    • 04 Oct 2018 According to a Vedanta Biosciences media release, additional exploration of VE303 in healthy volunteers to inform dose selection in other indications is ongoing.
    • 04 Oct 2018 Interim results presented in the Vedanta Biosciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top